Showing results (391-400 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|June 1, 2016
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority studyAlberto M La Rosa, Linda J Harrison, Babafemi Taiwo, et al.
The Lancet. HIV|August 7, 2017
Progress of UNAIDS 90-90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS study: a household-based complex multilevel community surveyAnneke Grobler, Cherie Cawood, David Khanyile, et al.
The Lancet. HIV|September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialPedro Cahn, Richard Kaplan, Paul E Sax, et al.
The Lancet. HIV|April 30, 2016
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trialMuktar H Aliyu, Meridith Blevins, Carolyn M Audet, et al.
The Lancet. HIV|April 30, 2016
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based surveyTendani Gaolathe, Kathleen E Wirth, Molly Pretorius Holme, et al.
The Lancet. HIV|April 30, 2022
Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort studyTaha E Taha, Nonhlanhla Yende-Zuma, Sean S Brummel, et al.
The Lancet. HIV|September 4, 2018
Ethical considerations in global HIV phylogenetic researchCordelia E M Coltart, Anne Hoppe, Michael Parker, et al.
The Lancet. HIV|October 2, 2019
Mosaic effectiveness: measuring the impact of novel PrEP methodsDavid V Glidden, Megha L Mehrotra, David T Dunn, et al.
The Lancet. HIV|March 19, 2019
Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trialEvgeny Krupitsky, Elena Blokhina, Edwin Zvartau, et al.
The Lancet. HIV|September 10, 2019
Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic studyKimberly K Scarsi, Yoninah S Cramer, Susan L Rosenkranz, et al.
Pageof 79